Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Witzig

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Cancer|December 1, 1994
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocolL C Hartmann, J N Ingle, L E Wold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|August 2, 2001
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemiaA Tefferi, C Y Li, C B Reeder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.
Leukemia & Lymphoma|December 28, 1999
Clinical significance of the translocation (11;14)(q13;q32) in multiple myelomaR Fonseca, J D Hoyer, P Aguayo, et al.
Bone Marrow Transplantation|December 2, 2000
Effect of complete response on outcome following autologous stem cell transplantation for myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.
Bone Marrow Transplantation|May 11, 2004
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapyS Kumar, M Q Lacy, A Dispenzieri, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Cancer|December 1, 1994
Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocolL C Hartmann, J N Ingle, L E Wold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia|August 2, 2001
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemiaA Tefferi, C Y Li, C B Reeder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.
Leukemia & Lymphoma|December 28, 1999
Clinical significance of the translocation (11;14)(q13;q32) in multiple myelomaR Fonseca, J D Hoyer, P Aguayo, et al.
Bone Marrow Transplantation|December 2, 2000
Effect of complete response on outcome following autologous stem cell transplantation for myelomaS V Rajkumar, R Fonseca, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.
Bone Marrow Transplantation|May 11, 2004
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapyS Kumar, M Q Lacy, A Dispenzieri, et al.
Pageof 19